Buserelin long - official instructions for use. Why you can not combine alcoholic beverages and buserelin depot

Treatment of uterine fibroids with Buserelin-Long should be started in the first days of the menstrual cycle. As a rule, this agent for combating malignant neoplasms is used when tumor growth depends on the production of hormones. Before using the medicine, you should always consult with a specialist about the negative consequences of the drug for the body.

The effective antitumor agent Buserelin-Long is a synthetic analogue of natural GnRH (gonadotropin-releasing hormone). The basis of the action of this drug is the competitive binding of pituitary cells to receptors and the further short-term growth of sex steroids in plasma, which often leads to a complete blockage of gonadotropic hormones.

Suspension Buserelin-Long lowers the production of testosterone in men to the levels of the post-castration period. The concentration of estradiol in women while taking the drug reaches values that are characteristic of the postmenopausal phase. The drug for two weeks after the start of use is able to completely block the gonadotropic functions of the body. The medicine is produced in the form of a lyophilisate for the preparation of a special suspension and spray.

What is the difference between Buserelin-Depot and Buserelin-Long

Today on pharmacy shelves you can find a huge amount of funds called Buserelin. At the same time, medicines often have additional words: acetate, depot or long. Each of these drugs is developed and produced according to certain technologies. Only a doctor can determine which remedy is best suited for treatment. The difference between Buserelin-Long and Buserelin-Depot is reflected in the comparative table:

Buserelin
Active substance
Treatment method	nasal spray	Intramuscular injections

Auxiliary components	Benzalkonium chloride, water for injections.	carmellose sodium; lactic, glycolic acids; polysorbate-80, mannitol.
Released	By prescription
Shelf life		Ampoule with solvent - 3 years; bottle with lyophilisate - no more than 2 years.
	from 700 to 3100 rubles	3500 rubles

Composition and form of release

The Russian pharmacy chain offers its consumers the Buserelin antitumor drug in two forms of release: a nasal spray for administering the drug through the nose and a powder composition for preparing a special solution (lyophilizate) that is administered intramuscularly. As a rule, a blister pack contains an ampoule with a solvent, a vial with a drug, 2 sterile needles and alcohol wipes, a disposable syringe, and a scarifier. The composition of Buserelin-Long is presented in the table:

Pharmacodynamics and pharmacokinetics

Buserelin has an antiandrogenic antitumor effect. When using the drug, a process of intensive release of gonadotropins can be observed. In this case, patients experience a short-term increase in the number of sex hormones. After 2 weeks, the action of the drug blocks the gonadotropic function of the pituitary gland, i.e. the secretion of estrogen stops, which stimulate the production of lutein and the formation of follicles.

The drug inhibits the synthesis of sex hormones, which is manifested by a decrease in the accumulation of estradiol to postmenopausal levels in women and a decrease in testosterone levels to the state of orchiectomy, pharmacological castration in men. The effect of the drug in the postoperative period reduces the formation of adhesions and the frequency of relapses. Pharmacokinetics: After intramuscular injection, there is a high bioavailability. The time to reach the maximum concentration of the substance after a single dose is 3 hours.

Indications for use

The drug Buserelin has proven itself in the treatment of infertility with the help of in vitro fertilization. The tool effectively suppresses the activity of the hormonal system, which helps to artificially control the maturation, fertilization and implantation of the egg. These manipulations help a woman quickly become pregnant. Therapy is carried out under the control of the concentration of the level of estradiol in the blood serum, in the absence of ovarian cysts, using ultrasound monitoring. In addition, doctors recommend using the remedy for:

endometriosis;
malignant neoplasm of the prostate (hormone-dependent cancer);
hyperplastic changes in the endometrium;
uterine myoma;
oncological diseases of the breast.

Instructions for use Buserelin-Long

The medical preparation Buserelin should be prescribed only by the attending physician. The suspension with the drug is prepared immediately before its administration using the supplied solvent. A health worker should prepare and inject the lyophilisate. Based on the individual characteristics of the patient, the duration and stage of the disease, the doctor determines the treatment regimen:

Uterine fibroids involves the introduction into the muscle of an injection of 3.75 mg of a solution of the drug once a day, repeated injections should be made after 4 weeks. Before surgery, treatment is carried out for several months, in other cases - six months.
In the treatment of prostate cancer, the drug should be administered intramuscularly at a dose of 3.75 mg with an interval of 4 weeks. The course of treatment takes a long period and is under the supervision of a doctor.
Hyperplastic changes in the endometrium suggest the start of therapeutic therapy from the 5th day of the menstrual cycle at a single dose of 3.75 mg. The course of treatment for endometriosis is six months.

special instructions

Even before the start of drug treatment, women should stop drinking hormonal contraceptives and exclude pregnancy. Often at the beginning of the use of an anticancer agent, the appearance of an ovarian cyst is possible. After discontinuation of the drug, the function of the gonads resumes. Menstruation is restored after 3 months. Ovulation induction is performed only under medical supervision.

To prevent the occurrence of negative consequences, men are advised to take antiandrogens with this drug for 2 weeks after the first injection. Patients with depression during therapy must be under the supervision of a doctor. Patients who use an anticancer drug should avoid drinking alcohol and smoking.

drug interaction

Buserelin can sometimes reduce the effect of hypoglycemic agents. This should be taken into account in diabetic patients. With the simultaneous use of drugs that contain sex hormones (for example, with the induction of ovulation), ovarian hyperstimulation syndrome may occur. In addition, according to doctors, the combined use of estrogenic drugs often provokes the development of cysts. After discontinuation of drugs, ovarian function is restored.

Manufacturers of the drug do not indicate the consequences that may occur with the simultaneous use of Buserelin and alcohol, but, as a rule, it is better not to combine alcohol with the drug. The consequences of such a tandem are unpredictable and negative for the patient's body. Often, arrhythmia, increased blood pressure can be observed from the side of the heart. The endocrine system also suffers from this combination, so the patient feels a decrease in libido, excessive sweating, redness of the face.

Patients who decide to take alcoholic beverages along with the medicine note a lack of appetite, severe disorders of the digestive system (diarrhea or constipation), weight loss or sudden weight gain. Often, against the background of drinking strong drinks and taking the remedy, there is an increase in side effects that are characteristic of the drug. These include:

memory impairment;
drowsiness or insomnia;
dizziness;
decreased concentration;
nervousness;
vomit;
decreased acuity of hearing, vision;
headache;
depression;
nausea.

Side effects

Buserelin, like any complex hormonal drugs that are dispensed by prescription, have negative consequences for the body. The central nervous system can react to the drug with headaches, deviations in the processes of wakefulness and sleep, a decrease in the ability to remember, neuropsychic instability and fatigue. In addition, the drug can provoke the following side effects:

increased sweating;
development of depression;
mineral depletion of bones;
noise in ears;
pain in the lower abdomen;
hearing loss;
increasing pressure on the eyes;
decrease in sexual desire;
frequent flushes of blood to the face;
dryness of the vagina;
bleeding;
tachycardia;
constipation, nausea, diarrhea, vomiting;
loss of appetite;
hyperemia of the skin;
development of bronchospasm,
anaphylactic shock;
swelling;
thrombocytopenia;
hyperglycemia;
leukopenia;
urinary retention.

Contraindications

Buserelin-Long should not be taken by patients who suffer from high sensitivity to the main components of the antitumor agent. People who have a history of urinary tract obstruction should be more attentive to their well-being. In addition, it is unacceptable to take this drug:

patients with diabetes;
children under 12;
nursing mothers;
pregnant women;
men with malignant prostate tumors that have metastasized to the spine;
patients with arterial hypertension, depression.

Terms of sale and storage

You can buy Buserelin-Long in almost any pharmacy. The drug is dispensed only by prescription of the attending physician. Buserelin has been produced in Russia since 2003. The shelf life of the drug is on average 3 years. Store the medicine in a dry place, protected from light and children, at temperatures up to 25 ° C.

Buserelin substitutes

Buserelin is contained in the drug of the same name, it is also part of Suprefact Depot, Buserelin acetate, Suprefact, Buserelin-Depot, while their dosage form is represented by a solution, implants, nasal spray, lyophilizate for the preparation of a suspension with prolonged action. In addition, the following analogues of the drug can be found on the pharmaceutical market:

Catad_pgroup Anticancer

Buserelin long - official instructions for use

Registration number:

LCP-003576/10-210318

Trade name of the drug:

Buserelin-long

International non-proprietary name:

buserelin

Dosage form:

lyophilisate for the preparation of a suspension for intramuscular administration of prolonged action

Compound:

Ingredients per bottle:
Active substance:
Buserelin acetate 3.93 mg
(in terms of buserelin) 3.75 mg
Excipients:
DL-lactic and glycolic acid 200.0 mg copolymer
D-Mannitol 85.0 mg
Carmellose sodium 30.0 mg
Polysorbate-80 2.0 mg
Solvent for suspension preparation - Mannitol, solution 0.8%
Composition per 1 ml:
D-Mannitol 8.0 mg
Water for injection up to 1.0 ml
Description : clear colorless liquid
Reconstituted suspension: when the solvent is added and agitated, a homogeneous suspension of white or white with a slight yellowish tinge is formed; when standing, the suspension precipitates, but is easily resuspended on shaking; the suspension should pass freely into the syringe through the needle No. 0840

Pharmacotherapeutic group:

antineoplastic agent, gonadotropin-releasing hormone (GnRH) analogue

ATX code:

L02AE01

Pharmacological properties

Pharmacodynamics
Synthetic analogue of endogenous gonadotropin-releasing hormone (GnRH). Buserelin competitively binds to the receptors of the cells of the anterior pituitary gland, causing a short-term increase in the level of sex hormones in the blood plasma, which subsequently leads to a complete reversible blockade of the gonadotropic function of the pituitary gland, thus inhibiting the release of luteinizing (LH) and follicle-stimulating hormone (FSH). As a result, suppression of the synthesis of sex hormones in the gonads is observed, which is manifested by a decrease in the concentration of estradiol in the blood plasma to post-menopausal values in women and a decrease in testosterone levels to post-castration levels in men. After the first administration of buserelin, by day 21 in men, the testosterone concentration decreases to the post-castration level (characteristic of the state of orchidectomy), i.e. called pharmacological castration. And in women, the concentration of estradiol decreases to a level corresponding to ovariectomy or postmenopause. The concentration of testosterone and estradiol remains reduced during the entire period of treatment, carried out every 28 days, which leads to inhibition of growth and regression of hormone-dependent tumors. After cessation of treatment, the physiological secretion of hormones is restored.

Pharmacokinetics
Bioavailability is high. The maximum plasma concentration is reached approximately 2-3 hours after intramuscular injection and remains at a level sufficient to inhibit the synthesis of gonadotropins by the pituitary gland for at least 4 weeks.

Indications for use

Hormone-dependent prostate cancer;
Mammary cancer;
Endometriosis (pre- and postoperative periods);
uterine fibroids;
Hyperplastic processes of the endometrium;
Treatment of infertility (during the program of in vitro fertilization (IVF)).

Contraindications

Pregnancy;
lactation period;
Hypersensitivity to components

Dosage and administration

In breast cancer and hormone-dependent prostate cancer, Buserelin-long is administered at a dose 3.75 mg (1 injection) intramuscularly (IM) every 4 weeks for a long time under medical supervision.
In the treatment of endometriosis, hyperplastic processes of the endometrium, the drug is administered at a dose 3.75 mg IM once every 4 weeks. Treatment should begin in the first five days of the menstrual cycle. Duration of treatment - 4 - 6 months.
In the treatment of uterine fibroids, Buserelin-long is administered at a dose 3.75 mg IM once every 4 weeks. Treatment should begin in the first five days of the menstrual cycle. Duration of treatment - before surgery 3 months, in other cases - 6 months;
In the treatment of infertility by in vitro fertilization (IVF)
Buserelin-long is administered at a dose of 3.75 mg (1 injection) intramuscularly once at the beginning of the folliculin phase (on the 2nd day of the menstrual cycle) or in the middle of the luteal phase (21-24 days) of the menstrual cycle preceding stimulation. After blockade of the pituitary function, confirmed by a decrease in the concentration of estrogens in the blood serum by at least 50% of the initial value (usually determined 12-15 days after the injection of Buserelin-long), in the absence of ovarian cysts (according to ultrasound), the thickness of the endometrium does not more than 5 mm, stimulation of superovulation with gonadotropic hormones begins under ultrasound monitoring and control of the concentration of estradiol in the blood serum.
Rules for the preparation of a suspension and administration of the drug

The drug is administered only intramuscularly
Suspension for intramuscular injection is prepared immediately before administration using the supplied solvent.
The drug should be prepared and administered only by specially trained medical personnel.
Keep the bottle with Buserelin-long strictly upright. Lightly tapping the vial, make sure that all the lyophilisate is at the bottom of the vial.

Open the syringe, attach a 1.2 mm x 50 mm needle to it to withdraw the solvent.
Open the ampoule with the solvent and draw the entire contents of the ampoule into the syringe, set the syringe to a dose of 2 ml.

Remove the plastic cap from the vial containing the lyophilisate. Disinfect the rubber stopper of the vial with an alcohol swab. Insert the needle into the lyophilizate vial through the center of the rubber stopper and carefully inject the solvent along the inner wall of the vial without touching the contents of the vial with the needle. Remove the syringe from the vial.

The vial should remain motionless until the lyophilizate is completely soaked with solvent and the suspension is formed (approximately 3 - 5 minutes). After that, without turning the vial over, check for the presence of dry lyophilisate at the walls and bottom of the vial. If dry residues of the lyophilizate are found, leave the vial until completely soaked.
After you have made sure that there are no residues of dry lyophilisate, gently mix the contents of the vial in circular motions for 30-60 seconds until a homogeneous suspension is formed. Do not invert or shake the vial.

Quickly insert the needle through the rubber stopper into the vial. Then lower the needle section down and, tilting the vial at an angle of 45 degrees, slowly draw the entire suspension into the syringe. Do not turn the vial upside down while typing. A small amount of the drug may remain on the walls and bottom of the vial. The consumption for the residue on the walls and bottom of the vial is taken into account. Immediately after taking the solution, remove the needle. Change to a 0.8 mm x 40 mm needle, carefully invert the syringe and remove air from the syringe.
Suspension Buserelin-long enter immediately after preparation.
Using an alcohol swab, disinfect the injection site: Insert the needle deep into the gluteal muscle, then pull the syringe plunger back slightly to make sure that there is no damage to the vessel. Enter the suspension slowly with constant pressure on the syringe plunger.
If the needle becomes clogged, replace it with another needle of the same diameter.

With repeated injections, the left and right sides should be alternated.

Side effect

Adverse reactions registered more often than single observations are listed below by organs and systems, indicating the frequency of their occurrence.
The frequency of adverse reactions that may occur during therapy is given as the following gradation: very often (>10%), often (>1% and<10 %), нечасто (>0.1% and<1%), редко (>0.01% and<0,1 %), очень редко (<0,01 %), частота неизвестна (отдельные сообщения о нежелательных явлениях, при которых установить частоту не всегда возможно).

For men and women:
Mental disorders: often - frequent mood swings, depression.
Nervous System Disorders: very often - sleep disturbances, headache.
Vascular disorders: very often - "hot flashes".
: often - urticaria, skin hyperemia, rarely - angioedema.
Musculoskeletal and connective tissue disorders: the frequency is unknown - with prolonged use - bone demineralization, which is a risk of developing osteoporosis.
Among women:
Heart disorders: often - palpitations.
Liver and biliary tract disorders: frequency unknown - increased activity of alanine aminotransferase in blood plasma, increased activity of aspartate aminotransferase in blood plasma.
Skin and subcutaneous tissue disorders: infrequently - increased sweating.
Musculoskeletal and connective tissue disorders: often - discomfort in the joints.
Genital and breast disorders: very often - a change in libido, dryness of the vaginal mucosa, menstrual bleeding (during the first weeks of treatment); often - pain in the lower abdomen.
In men in the treatment of prostate cancer: during the first 2-3 weeks after the first injection, buserelin can cause an exacerbation and progression of the underlying disease (associated with stimulation of the synthesis of gonadotropins and, accordingly, testosterone), a transient increase in the concentration of androgens in the blood.
Blood and lymphatic system disorders: in isolated cases (a causal relationship has not been clearly established) - pulmonary embolism.
Gastrointestinal disorders: in isolated cases (a causal relationship has not been clearly established) - dyspeptic disorders.
Skin and subcutaneous tissue disorders: frequency unknown - increased sweating.
Musculoskeletal and connective tissue disorders: frequency unknown- muscle weakness in the lower extremities. At the beginning of treatment in patients with prostate cancer, a temporary increase in bone pain may occur; in this case, symptomatic therapy should be carried out.
Renal and urinary tract disorders: infrequently - urinary retention. There have been isolated cases of ureteral obstruction and spinal cord compression.
Genital and breast disorders: very often - a decrease in potency (rarely requires discontinuation of therapy), often - gynecomastia.
General disorders and disorders at the injection site: often - "renal edema" - swelling of the face, eyelids, legs.

Overdose

No cases of overdose have been reported to date.

Interaction with other drugs

The simultaneous use of Buserelin-long with drugs containing sex hormones (for example, in the ovulation induction mode) may contribute to the occurrence of ovarian hyperstimulation syndrome.
With the simultaneous use of Buserelin-long may reduce the effectiveness of hypoglycemic agents.

special instructions

Among women
Patients with any form of depression during the period of drug treatment should be under the close supervision of a physician.
Ovulation induction should be carried out under strict medical supervision.
In the initial stage of drug treatment, the development of ovarian cysts is possible.
Before starting treatment, it is recommended to exclude pregnancy and stop taking hormonal contraceptives, however, during the first two months of using the drug, other (non-hormonal) methods of contraception should be used.
After stopping treatment, ovarian function is restored. The first menstruation resumes after 3 months.
In men
In order to effectively prevent possible side effects in the first phase of the drug, it is necessary to use antiandrogens two weeks before the first injection of Buserelin-long and for two weeks after the first injection.

Influence on the ability to drive vehicles and mechanisms

Care should be taken when prescribing the drug to patients involved in potentially hazardous activities that require increased attention and speed of mental and motor reactions.

Release form

Lyophilizate containing 3.75 mg of buserelin, in vials A little glass with a capacity of 10 ml. 2 ml of solvent (mannitol solution for injection 0.8%) in neutral glass ampoules.
By production at Nativa LLC, Russia.
Placed in a blister pack:

1 bottle with the drug;
1 ampoule with solvent;
1 disposable syringe with a capacity of 5 ml, packed in an individual blister pack;
1 sterile needle for injection, size 0.8 mm x HO mm, packed in a blister pack complete with a syringe;
1 sterile solvent needle, 1.2 mm x 50 mm in size, packed in a blister pack;
1 knife for opening ampoules or 1 scarifier;
2 alcohol wipes individually wrapped.
When packing the solvent into imported ampoules with opening rings or a break point, an ampoule scarifier or a knife for opening ampoules is not included.
1 or 2 contour cells
1 package, together with instructions for use, is placed in; cardboard pack.
Or, in the production at JSC Pharmstandard-UfaVITA, Russia.
Placed in a blister pack:
1 bottle with the drug;
1 ampoule with solvent;
1 disposable syringe, 5 ml capacity, complete with 1 sterile injection needle, 0.8 mm x 40 mm, packed in a blister pack;
1 sterile solvent needle, size 1.2 mm x 50 mm, packed in an individual blister pack;
2 alcohol wipes, individually wrapped.
1 or 2 blisters, together with instructions for use, are placed in a cardboard box.

Storage conditions

In a place protected from light at a temperature not exceeding 25 ° C.
Keep out of the reach of children.

Best before date

Lyophilisate - 2 years.
Solvent - 3 years.
Do not use after the expiration date indicated on the package.

Holiday conditions

Released by prescription.

Manufacturer

Registration certificate holder: OOO Nativa, Russia Legal address:
143402,; Russia, Moscow region, Krasnogorsk, st. Oktyabrskaya, 13;
In production at Nativa LLC, Russia indicate:
OOO Nativa, Russia
Legal address: 143402, Russia, Moscow region, Krasnogorsk, st. Oktyabrskaya, 13
Or, in the production at JSC "Pharmstandard-UfaVITA", Russia indicate:
Producer / organization accepting consumer claims
OJSC Pharmstandard-UfaVITA, Russia
450077, Republic of Bashkortostan, Ufa, st. Khudaiberdina, 28

Buserelin- depot
Latin name: Buserelin-depo
Pharmacological groups: Hyp hormones from alamus, pituitary, gonads from ropins and their antagonists. Etc from
pharmachologic effect

Application: fromfromfrom burning (ECO).

Etc from and indications: Hypersensitivity.

Application restrictions:

Etc from from seem from breastfeeding.

Side effects:
From the digestive tract: change in appetite, nausea from a, rv from A.
decreased libido, imp fromfrom a, menstrual blood from treatment.
Allergic reactions: from ic from ec.
Others: fromfrom O from from

Interaction:from

Dosage and administration: V / m, s / c, intranasally.

Mammary cancer:

Precautionary measures:
buserelin A.

fromfrom

Special instructions:from ry on side effects, to from

Buserelin-depot (Buserelin-depo)

Buserelin
Latin name: Buserelin
Pharmacological groups: Hyp hormones from alamus, pituitary, gonads from ropins and their antagonists. Etc from cancerous hormones and hormone antagonists
Nosological classification (ICD-10): C50 Malignant neoplasms of the mammary gland. C61 Malignant neoplasm of the prostate. D25 Leiomyoma of the uterus. D26 Other benign neoplasms of uterus. N80 Endometriosis. N85.0 Glandular hyperplasia of endometrium. N85.1 Adenomatous hyperplasia of endometrium. N97 Female infertility
pharmachologic effect

Active ingredient (INN) Buserelin (Buserelin)
Application: Hormone-dependent prostate cancer stage III and IV (if necessary, inhibition of testosterone production in the testes); breast cancer in women with a preserved menstrual cycle and the presence of estradiol / progesterone receptors; hormone-dependent pathology of the reproductive system, caused by absolute or from relative hyperestrogenism (endometriosis, including pre- and postoperative periods, uterine fibroids, endometrial hyperplastic processes); for induction of ovulation in the treatment of infertility (in combination with gonadal from ropins) in in vitro fertilization programs from burning (ECO).

Etc from and indications: Hypersensitivity.

Application restrictions: History of urinary tract obstruction, metastases to the spine - due to the risk of spinal cord compression as a result of an exacerbation of the disease (prostate cancer) at the beginning of treatment.

Use during pregnancy and lactation: Etc from and indicated in pregnancy. At the time of treatment, from seem from breastfeeding.

Side effects:From the nervous system and sensory organs: headache (with intranasal administration), mood lability, sleep disturbance, depression, eye irritation symptoms (when wearing contact lenses).
From the digestive tract: change in appetite, nausea from a, rv from A.
From the genitourinary system: decreased libido, imp from ence, vaginal dryness, ovarian cysts, lower pain alive from a, menstrual blood from treatment.
Allergic reactions: urticaria, skin hyperemia, angioedema from ic from ec.
Others: hot flashes, irritation of the nasal mucosa and nasal blood from treatment (with intranasal administration), increased p from O from division (with intranasal administration), acne, dry skin and mucous membranes, bone demineralization, gynecomastia, thrombosis, from stiffness of the feet and ankle joints; symptoms associated with an increase in blood testosterone levels at the beginning of therapy (bone pain, numbness or tingling in the hands or feet, difficulty urinating, weakness in the legs).

Interaction: Simultaneous use with other drugs containing sex hormones (including gonads from ropina - in the induction of ovulation), may contribute to the occurrence of ovarian hyperstimulation syndrome. Reduces the effect of hypoglycemic agents.

Dosage and administration: V / m, s / c, intranasally.
Hormone dependent prostate cancer: i / m, 3.75 mg once every 4 weeks or s / c 0.5 mg 3 times a day for 7 days, then maintenance intranasal therapy at a dose of 0.9 - 1.2 mg / day in 4 injections up to disease progression.
Mammary cancer: intranasally, 0.9 mg / day in 3 injections.
Endometriosis, endometrial hyperplasia, uterine fibroids: i / m, 3.75 mg once every 4 weeks for 4-6 months (with uterine myoma - within 3 months before surgery; with conservative treatment - 6 months); treatment should begin in the first 5 days of the menstrual cycle. Intranasally 0.9 mg / day in 3 injections; start treatment on day 1 or 2 of the menstrual cycle, no more than 6 months (risk of osteoporosis).
IVF infertility treatment: i / m, 3.75 mg once on the 2nd day of the menstrual cycle or s / c, 0.2-0.5 mg 1 time per day for 1-3 weeks before the introduction of hCG starting from day 1 or (if pregnancy is excluded) from the 21st day of the menstrual cycle (the maximum dose is 0.5 mg 2 times a day). Intranasally, 0.6 mg / day in 4 injections for 1-3 weeks, starting from day 1, with the exclusion of pregnancy - from day 21 of the menstrual cycle to the introduction of hCG. The maximum dose is 1.2 mg / day. The repeated course is carried out under dynamic hormonal control and ultrasound monitoring.

Precautionary measures: Before starting therapy, it is necessary to exclude the presence of pregnancy and stop taking oral contraceptives; during the first 2 months of treatment of endometriosis, endometrial hyperplasia and uterine fibroids, it is necessary to use barrier methods of contraception (condoms).
When administered intranasally against the background of rhinitis, it is necessary to clear the nasal passages before administration; the use of intranasal vasoconstrictors should be avoided before and for 30 minutes after administration buserelin A.
Use with caution in patients with depression.
For ovulation induction, it can only be prescribed by a doctor experienced in the treatment of infertility.
Use with caution during work from s drivers of vehicles and people, activities to from Some of them are associated with increased concentration of attention.

Special instructions: For the treatment of prostate cancer should not be prescribed to patients after orchiectomy. At the beginning of treatment for prostate cancer, an exacerbation of the disease (usually less than 10 days) is possible, associated with an initial transient increase in the concentration of androgens in the blood (“flare phenomenon”). In this case, severe pain in the bones or at the site of the tumor, exacerbation of symptoms (including dysuria) are possible. Strengthening of neurological disorders in patients with spinal metastases can lead to temporary weakness and paresthesia in the lower extremities. The patient should be warned about the need to continue therapy. from ry on side effects, to from which decrease or disappear during further treatment.

Buserelin (Buserelin)

Cytochrome C yeast- long
Latin name: Cytochromum C
Pharmacological groups: Antihypoxants and antioxidants. Regenerants and reparants
Nosological classification (ICD-10): B15-B19 Viral hepatitis. H30-H36 Diseases of the choroid and retina. I25 Chronic ischemic heart disease. J18 Pneumonia without specification of the causative agent. J45 Asthma. R06 Abnormal breathing. T40 Drug poisoning from icami and psychodysleptics [hallucinogens]. T51 Toxic effect of alcohol
pharmachologic effect

Active ingredient (INN) Cytochrome C (Cytochrome C)
Application: Asphyxia of newborns, bronchial asthma, heart failure, ischemic heart disease, infectious hepatitis.

Etc from and indications: Hypersensitivity.

Side effects: allergic reactions; with rapid on / in the introduction - chills and fever.

Dosage and administration: In / in: dilute 10-100 mg of the drug in 200 ml of from an onic solution of sodium chloride or 5% glucose solution is administered intravenously at a rate of 30-40 drops per minute; i / m: 5-20 mg 1-2 times a day. The course of treatment is 10-14 days. Before parenteral use, a test for individual tolerance is necessary (in / to 0.25 mg with an assessment of the result after 30 minutes). Inside: 20 mg 4 times a day for 5-10 days.

Cytochrome C yeast-long (Cytochromum C)

Active ingredient (INN) Buserelin (Buserelin)
Application: Hormone-dependent prostate cancer stage III and IV (if necessary, inhibition of testosterone production in the testes); breast cancer in women with a preserved menstrual cycle and the presence of estradiol / progesterone receptors; hormone-dependent pathology of the reproductive system, caused by absolute or from relative hyperestrogenism (endometriosis, including pre- and postoperative periods, uterine fibroids, endometrial hyperplastic processes); for induction of ovulation in the treatment of infertility (in combination with gonadal from ropins) in in vitro fertilization programs from burning (ECO).

Etc from and indications: Hypersensitivity.

Use during pregnancy and lactation: Etc from and indicated in pregnancy. At the time of treatment, from seem from breastfeeding.

Buserelin (-)

Insulin- long QMS
Latin name: Insulin longum SMC
Pharmacological groups: insulins
Nosological classification (ICD-10): E10 Insulin-dependent diabetes mellitus
Composition and form of release: 1 ml suspension for injection contains highly purified porcine insulin 40 IU; in vials of 10 ml.

Pharmachologic effect:Hypoglycemic. Regulates carbohydrate metabolism: lowers the level of glucose in the blood, increases its absorption by tissues.

Clinical pharmacology: The action begins after 1-3 hours, reaches a maximum after 6-12 hours and lasts 18-26 hours.

Indications: Insulin dependent diabetes mellitus.

Etc from and indications: Hypersensitivity, hyperglycemic coma.

Side effects: Allergic reactions, hypoglycemia, lipodystrophy at the injection site.

Overdose:Symptoms: hypoglycemia (feeling hungry, weak, from tremor, headache, palpitations), in severe cases - hypoglycemic coma (n from loss of consciousness, convulsions, depression of cardiac activity).
Treatment: taking sweet tea or sugar; with hypoglycemic coma - 20–40 ml (up to 100 ml) of 40% glucose solution intravenously, glucagon s / c.

Dosage and administration: PC; doses and number of injections are set individually, depending on from the general condition of the patient, the severity and characteristics of the course of the disease, the level of daily glucosuria and the glycemic profile.

Precautionary measures: Not intended for intravenous administration.

Special instructions: Before use, the bottle must be warmed to room temperature, shaken; bottle rubber cap from fuck with alcohol or yo

Insulin-long SMC (Insulinum-longum SMC)

Active ingredient (INN) Goserelin (Goserelin)
Application: Hormone-dependent prostate cancer, hormone-dependent breast cancer in women in the reproductive period, endometriosis, uterine fibroids, dysfunctional uterine blood from treatment, carrying out methods of in vitro fertilization from cooking (preparing from ovation to superovulation).

Etc from and indications: Hypersensitivity, pregnancy, lactation, children and adolescence (up to 14 years).

Use during pregnancy and lactation: Etc from and indicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects: In men - obstruction of the ureters, spinal cord compression syndrome; in women - dryness of the vaginal mucosa, hot flashes, changes in mood and sexual desire, menopause, amenorrhea (after from exchange), spotting (in the beginning); instability of blood pressure, allergic reactions (skin rash, anaphylaxis).

Dosage and administration: S / c (if necessary under local anesthesia), depot 3.6 mg in the anterior abdominal wall every 28 days, depot 10.8 mg (only for treatment of prostate cancer) every 12 days. For thinning of the endometrium, it is administered twice with an interval of 4 weeks (the operation must be performed no later than within 2 weeks after the second injection). Benign gynecological diseases are treated for 6 months.

Precautionary measures: It is prescribed with caution at the risk of urinary tract obstruction and spinal cord compression syndrome. Repeated courses for benign gynecological diseases are not recommended due to the high probability of manifestations of osteoporosis.

Goserelin (-)

Adamon long 200
Latin name: Adamon long 200
Pharmacological groups:
Nosological classification (ICD-10):fromfrom
pharmachologic effect

Application:

Etc from and indications: from

Side effects: Addiction, syndrome fromfromfrom oniya, collapse, nausea fromfrom

Interaction:from

Overdose:Symptoms: respiratory depression, vpl from
Treatment:

Dosage and administration: from

Adamon long 200 (Adamon long 200)

Adamon long 150
Latin name: Adamon long 150
Pharmacological groups: Opioids, their analogues and antagonists
Nosological classification (ICD-10): I21 Acute myocardial infarction. M25.5 Pain in the joint. M79.2 Neuralgia and neuritis, unspecified R07.2 Pain in the region of the heart. R10.1 Pain localized in the upper part of the living from A. R10.4 Other and unspecified pain in vein from A. R52 Pain, not elsewhere classified. R52.0 Sharp pain. R52.1 Persistent intractable pain. R52.2 Other persistent pain. T08-T14 Injury of unspecified part of trunk, limb or body region. T88 Other complications of surgery and medical procedures, not elsewhere classified Z100 CLASS XXII Surgical practice
pharmachologic effect

Active ingredient (INN) Tramadol (Tramadol)
Application: Pain syndrome of moderate intensity in malignant neoplasms, acute myocardial infarction, trauma, diagnostic and therapeutic procedures, neuralgia.

Etc from and indications: Hypersensitivity, acute alcohol from administration and intoxication with depriming agents and drugs that depress the central nervous system, epilepsy, impaired liver and kidney function, pregnancy, breastfeeding (suspended for the duration of treatment), early childhood (up to 2 years).

Side effects: Addiction, syndrome from addiction, dizziness, lethargy, respiratory depression, dysphoria, euphoria, cognitive decline, convulsions, vomiting from a, tachycardia, palpitations, hip from oniya, collapse, nausea from a, pain in the epigastric region, p from a, constipation, difficulty urinating, allergic reactions.

Interaction: Enhances the effects of tranquilizers, sn from drugs, sedatives and anesthetics, alcohol.
Activity is reduced by analeptics and psychostimulants, completely blocked by naloxone and naltrexone (direct antagonists). In combination with neuroleptics, it can cause convulsions.

Overdose:Symptoms: respiratory depression, vpl from to apnea, convulsions, pupillary constriction, anuria, coma.
Treatment: administration of naloxone (specific antagonist) intravenously, gastric lavage, maintenance of vital functions.

Dosage and administration: Inside adults and children over 14 years old - 50 mg, (again - not earlier than in 30-60 minutes). Parenterally - 50-100 mg, rectally - 100 mg (re-introduction of suppositories is possible after 3-5 hours). The maximum daily dose is 400 mg. Children aged from 2 to 14 years inside (drops) or parenterally - 1-2 mg / kg.

Adamon long 150 (Adamon long 150)

Adamon long 100
Latin name: Adamon long 100
Pharmacological groups: Opioids, their analogues and antagonists
Nosological classification (ICD-10): I21 Acute myocardial infarction. M25.5 Pain in the joint. M79.2 Neuralgia and neuritis, unspecified R07.2 Pain in the region of the heart. R10.1 Pain localized in the upper part of the living from A. R10.4 Other and unspecified pain in vein from A. R52 Pain, not elsewhere classified. R52.0 Sharp pain. R52.1 Persistent intractable pain. R52.2 Other persistent pain. T08-T14 Injury of unspecified part of trunk, limb or body region. T88 Other complications of surgery and medical procedures, not elsewhere classified Z100 CLASS XXII Surgical practice
pharmachologic effect

Adamon long 100 (Adamon long 100)

Adamon long 50
Latin name: Adamon long 50
Pharmacological groups: Opioids, their analogues and antagonists
Nosological classification (ICD-10): I21 Acute myocardial infarction. M25.5 Pain in the joint. M79.2 Neuralgia and neuritis, unspecified R07.2 Pain in the region of the heart. R10.1 Pain localized in the upper part of the living from A. R10.4 Other and unspecified pain in vein from A. R52 Pain, not elsewhere classified. R52.0 Sharp pain. R52.1 Persistent intractable pain. R52.2 Other persistent pain. T08-T14 Injury of unspecified part of trunk, limb or body region. T88 Other complications of surgery and medical procedures, not elsewhere classified Z100 CLASS XXII Surgical practice
pharmachologic effect

Adamon long 50 (Adamon long 50)

Buserelin is an agent for fighting malignant tumors. The drug is used if the growth of the neoplasm depends on the production of hormones. In the treatment of such tumors, synthetic analogues of pituitary releasing hormones are used. Buserelin is one such analogue of natural hormones. Buserelin long is a prolonged form of the drug. Due to the long action, it is used once every few weeks.

In contact with

The composition of the drug

The medicinal substance of the drug is Buserelin acetate. The composition of the drug also includes copolymer compounds of lactic and glycolic acids, carmellose sodium, polysorbate-80 and d-mannitol. Busereling Long is available as a powder. It is diluted in a solvent and injected intramuscularly. The powder bottle contains 3.75 mg of the active ingredient - Buserelin acetate. One package of Buserelin Long contains a bottle of powder, a solvent in an ampoule, a syringe, 2 needles (for solvent and for injection), 2 napkins and a knife for opening the ampoule.

The medicinal effect of the drug

At the first stage of treatment with the drug, the content of gonadotropins and sex hormones increases. This increase in hormonal levels is temporary.

14 days after the injection of Buserelin long production of gonadotropins by the pituitary gland is blocked. In women, the production of pituitary hormones responsible for the maturation of follicles in the ovaries stops. As a result, the level of female sex hormones is sharply reduced. The content of estrogen in young women falls to the levels characteristic of the menopause. Doctors call this condition medical pseudomenopause.

In men, the action of the drug leads to a sharp drop in the level of androgens (male sex hormones). The indicators of sex hormones fall to the level of the post-castration period. Doctors call it pharmacological castration. Patients need to remember that during treatment with Buserelin Long, the decrease in estrogen and androgen levels is reversible. After cessation of therapy, the content of sex hormones returns to normal levels.

For what diseases is the drug used?

Instructions for use Buserelin long speaks of the following indications for treatment drug:

diseases of the uterus caused by an excess of estrogens (uterine fibroids, endometriosis, endometrial hyperplasia);
breast tumors (with intact menstrual function and intact estrogen and progesterone receptors);
before and after operations for endometriosis (the drug reduces endometriosis lesions and the formation of adhesions after surgery);
hormone-dependent forms of prostate cancer;
before in vitro fertilization (IVF) - the drug suppresses the natural synthesis of estrogens, which makes it possible to create an artificial hormonal status necessary for embryo replanting.

Who should not take Buserelin Long?

Buserelin long is a potent drug that greatly changes the hormonal status of a person. That's why Not every patient is shown such a tool:

Possible side effects when taking the drug

When treated with such a potent drug side effects not excluded.

From the side of the central nervous system, dizziness, headache, insomnia, memory loss and absent-mindedness, fatigue are possible. Those suffering from depressive disorders may worsen their mental state.
On the part of the sense organs, hearing and vision impairment, tinnitus, a feeling of pressure on the eyes are possible.
The cardiovascular system may also respond to the drug. Possible increase in blood pressure, tachycardia.
Manifestations from the digestive organs are expressed in dyspeptic symptoms, impaired appetite.
In patients prone to allergies, skin rashes and itching are possible. Bronchospasm, anaphylactic shock, and edema are very rarely observed.
Very often there are side effects from the endocrine organs, since the drug is an analogue of pituitary hormones. Many women complain of flushing to the face, increased sweating, decreased libido, pain in the lower abdomen, increased bone fragility, dryness in the vagina. This is due to the ability of Buserelin long to dramatically reduce the level of female sex hormones. In men, due to a low level of androgens, there is an increase in the mammary glands (gynecomastia), a decrease in potency, rare and difficult urination.
In patients undergoing treatment for prostate cancer, symptoms may worsen in the first days of treatment with the drug.
All side effects are aggravated by the use of alcohol during the course of treatment.

During therapy with Buserelin long, changes in the blood test are possible: a decrease in leukocytes and platelets, an increase in glucose levels, changes in the lipid composition of the blood.

Buserelin long treatment regimen

This drug belongs to potent drugs, so its use is permissible only as directed by a doctor.

In the treatment of malignant tumors of the breast and prostate make 1 injection (3.75 mg) intramuscularly 1 time in 4 weeks. The course of treatment takes a long time and is carried out under close medical supervision.

In the treatment of pathologies of the female genital organs associated with an excess of estrogen (endometriosis, fibroids, endometrial hyperplasia), also give 1 injection every 4 weeks. According to the instructions for the drug, treatment begins in the first 5 days of the menstrual cycle. The course of treatment lasts from 3 to 6 months. Therapy before surgery for uterine fibroids should last about 3 months.

Before the IVF procedure the first injection of Buserelin long is done either on the second day of the menstrual cycle, or in the period from the 21st to the 24th day. Two weeks after the injection, the level of estrogen decreases by 2 times. After that, an ultrasound examination is done to exclude ovarian cysts. Then, with the help of gonadotropic hormones, superovulation is stimulated under ultrasound monitoring.

special instructions

The instructions for the drug indicate features of the use of Buserelin long.

Interaction of buserelin with other drugs

The drug is not recommended for use together with estrogenic agents. Simultaneous use of Buserelin and estrogens can cause ovarian hyperstimulation and cyst formation. Buserelin may reduce the effect of the use of hypoglycemic drugs. This should be borne in mind by diabetic patients taking medication.

Many patients are interested in the cost per bottle of Buserelin Long. The price of this medicine in pharmacies can be from 3500 to 5500 rubles. Analogues of the drug for the active substance are:

The closest remedy is Buserelin depot. Both drugs are generics of the same drug.